Molecular structure of Imatinib mesylate, CAS Number: 220127-57-1
Imatinib mesylate (CAS 220127-57-1)
See product citations (61)
Alternate Names:
Imatinib mesylate is also known as Imatinib methanesulfonate salt.
Application:
Imatinib mesylate is a c-Abl, PDGFR, and c-kit inhibitor that halts chronic myelogenous leukemia related growth.
CAS Number:
220127-57-1
Purity:
≥99%
Molecular Weight:
589.71
Molecular Formula:
C29H31N7O•CH3SO3H
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Imatinib mesylate is a small molecule that inhibits the c-Abl protein-tyrosine kinase, a kinase specifically important for proliferation of chronic myelogenous leukemia (CML). A translocation event between chromosomes 9 and 22 generates the Philadelphia chromosome, which then produces the Bcr-Abl fusion protein with aberrant kinase activity that promotes rapid cell proliferation. Imatinib mesylate binds up this kinase, halting CML related growth. Imatinib mesylate has further been displayed to inhibit PDGFR and tyrosine kinases associated with c-Kit. Formulations containing Imatinib mesylate have been used in the treatment of various cancers.
Imatinib mesylate (CAS 220127-57-1) References
- Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. | Buchdunger, E., et al. 2000. J Pharmacol Exp Ther. 295: 139-45. PMID: 10991971
- Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. | Kantarjian, HM. and Talpaz, M. 2001. Semin Oncol. 28: 9-18. PMID: 11740802
- Imatinib mesylate. | Baker, DE. 2002. Rev Gastroenterol Disord. 2: 75-86. PMID: 12122963
- LRP: role in vascular wall integrity and protection from atherosclerosis. | Boucher, P., et al. 2003. Science. 300: 329-32. PMID: 12690199
- Imatinib mesylate in the treatment of chronic myeloid leukaemia. | Druker, BJ. 2003. Expert Opin Pharmacother. 4: 963-71. PMID: 12783592
- Imatinib mesylate in the treatment of gastrointestinal stromal tumour. | Steinert, DM., et al. 2005. Expert Opin Pharmacother. 6: 105-13. PMID: 15709888
- Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. | Chhina, MK., et al. 2010. Future Cardiol. 6: 19-35. PMID: 20014985
- Imatinib mesylate for the treatment of gastrointestinal stromal tumor. | Cassier, PA. and Blay, JY. 2010. Expert Rev Anticancer Ther. 10: 623-34. PMID: 20469993
- Imatinib mesylate-induced pseudoporphyria. | Berghoff, AT. and English, JC. 2010. J Am Acad Dermatol. 63: e14-6. PMID: 20542169
- Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes. | Stagno, F., et al. 2016. Expert Rev Anticancer Ther. 16: 273-8. PMID: 26852913
- Imatinib mesylate-induced lichenoid drug eruption. | Penn, EH., et al. 2017. Cutis. 99: 189-192. PMID: 28398413
- Dermatofibrosarcoma Protuberans. | Allen, A., et al. 2019. Dermatol Clin. 37: 483-488. PMID: 31466588
- Imatinib Mesylate Exerted Antitumor Effect by Promoting Infiltration of Effector T Cells in Tumor. | Hirata, A., et al. 2022. Biol Pharm Bull. 45: 34-41. PMID: 34980779
- Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. | Buchdunger, E., et al. 1996. Cancer Res. 56: 100-4. PMID: 8548747
Inhibitor of:
2700090O03Rik, 3BP1, 6130401L20Rik, AADACL4, AI314976, AI324046, AI462493, AI597468, ATF-2, BC005537, BC006662, BC015286, BC016579, BC017647, BC018465, BC020535, c-Abl, c-Kit, C14orf82, C1orf170, C530044N13Rik, C5orf49_1700001L19Rik, CEACAM2, CHES1, CRLF1, CTGLF1, CXorf59, Ddc8, DNAH14, EIG121, FAF1, FAM196A, FAM75C1, Gm960, HLA-F`, HORMAD2, IGFL1, INSM2, Keratin 33A, KIAA0802, KIAA1432, KRTAP5-11, LAIR-1, LDOC1, Lefty, LOC100041190, LOC100041292, LOC728504, Ly-49C, MAGE-D4B, MAL2, MFRP, MS4A13, MYADM, Myeloid lineage, N-Shc, nemo II, NET-4, NK10, NKp44, NUCKS, Olr1014, Olr1203, OTTMUSG00000016644, PDGF-C, PDGFR, PDIK1L, PHAX, PKR1, Proliferation Marker, PTRF, Ran BP-5, Sad-1, SCFD1, Sg III, SIRP-β2, SmcY, SP-lyase, SR-6, TMIGD2, TTYH1, Tyrosine Kinase, UMPS, V1RD16, V1RD18, Vmn2r92, WFIKKN2, WHIP, Zip67, ZNF177, ZNF285A, ZNF302, ZNF43, ZNF433, ZNF443, ZNF444, ZNF45, ZNF468, ZNF480, ZNF528, ZNF530, ZNF540, ZNF546, and ZNF549.Activator of:
Bex2, Cbl-b, CD151, EG232801, EphA6, ephrin-B2, FRNK, HACS1, IgG4, Importin-9, KOR-1, L-type calcium channel α1D, L-type calcium channel α1F, Lnk, Mcl-1, MLF2, PID1, PRX1, SLAMF6, and uPA.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Imatinib mesylate, 25 mg | sc-202180 | 25 mg | $45.00 | |||
Imatinib mesylate, 100 mg | sc-202180A | 100 mg | $111.00 |